Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
STA-4783
Known as:
STA 4783
, STA4783
National Institutes of Health
Create Alert
Related topics
Related topics
2 relations
Elesclomol Sodium
Broader (1)
elesclomol
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Lipopolysaccharide and heat stress impair the estradiol biosynthesis in granulosa cells via increase of HSP70 and inhibition of smad3 phosphorylation and nuclear translocation.
H. Li
,
Shuangshuang Guo
,
L. Cai
,
W. Ma
,
Z. Shi
Cellular signalling
2017
Corpus ID: 33484535
LPS and heat stress have been shown to exert various toxic effects in animals, as they induce estradiol biosynthesis dysfunction…
Expand
Review
2015
Review
2015
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy
M. C. Caino
,
D. Altieri
Clinical Cancer Research
2015
Corpus ID: 10276135
Small-molecule inhibitors of the phosphoinositide 3-kinase (PI3K), Akt, and mTOR pathway currently in the clinic produce a…
Expand
2013
2013
Syntheses and antitumor activities of N'1,N'3-dialkyl-N'1,N'3-di-(alkylcarbonothioyl) malonohydrazide: the discovery of elesclomol.
Shoujun Chen
,
Lijun Sun
,
+10 authors
A. Sonderfan
Bioorganic & medicinal chemistry letters
2013
Corpus ID: 2792900
A series of N'(1),N'(3)-dialkyl-N'(1),N'(3)-di(alkylcarbonothioyl) malonohydrazides have been designed and synthesized as…
Expand
Review
2008
Review
2008
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
J. Weber
The oncologist
2008
Corpus ID: 8023402
Targeted biologic therapies such as anti-cytotoxic T lymphocyte antigen (CTLA-4) monoclonal antibodies, either as monotherapy or…
Expand
2007
2007
Phase I Clinical Trial of STA-4783 in Combination with Paclitaxel in Patients with Refractory Solid Tumors
A. Berkenblit
,
J. Eder
,
+6 authors
J. Supko
Clinical Cancer Research
2007
Corpus ID: 25400211
Purpose: STA-4783 is a new compound that markedly enhances the therapeutic index of paclitaxel against human tumor xenograft…
Expand
2006
2006
Drug evaluation: STA-4783--enhancing taxane efficacy by induction of Hsp70.
M. Gehrmann
Current opinion in investigational drugs
2006
Corpus ID: 8362147
The apoptosis stimulator STA-4783 acts by inducing expression of heat shock protein (Hsp)70 on tumor cell surfaces and disrupting…
Expand
2005
2005
A phase 1/2 study of STA-4783 in combination with paclitaxel and carboplatin in chemo-naive advanced non-small cell lung cancer (NSCLC)
M. Jacobs
,
R. Weber
,
+7 authors
R. Salgia
2005
Corpus ID: 74339769
7106 Background: STA-4783 (S) is a bis-thiobenzoylhydrazide that induces heat shock protein 70 (hsp 70). S significantly enhanced…
Expand
2005
2005
A 2-stage controlled phase 1/2 study of STA-4783 in combination with paclitaxel in patients with advanced metastatic melanoma
J. D. Powderly
,
K. Khan
,
+5 authors
S. O’Day
2005
Corpus ID: 74144023
7561 Background: STA-4783 (S), a novel inducer of heat shock protein 70 (hsp70) is a bis-thiobenzoylhydrazide compound. S leads…
Expand
2005
2005
Phase 1/2 study of STA-4783, a novel heat shock protein 70 (hsp70) inducer, in combination with paclitaxel in patients with soft tissue sarcomas (STS)
M. Sherman
,
C. Ryan
,
+5 authors
G. D. Demitri
2005
Corpus ID: 73903536
9069 Background: STA-4783, a novel inducer of hsp70 is a bis-thiobenzoylhydrazide compound. STA-4783 leads to up regulation of…
Expand
2004
2004
STA-4783, a novel HSP inducer, enhances paclitaxel activity-Preclinical to clinical modeling.
R. Salgia
,
A. Berkenblit
,
B. Dezube
,
T. Dahl
,
K. Koya
Journal of clinical oncology : official journal…
2004
Corpus ID: 10922789
3124 Background: STA-4783 is a newly synthesized bis-thiobenzoylhydrazide (MW 400) that promotes tumor-specific induction of heat…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE